1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

Clinical Phenotypes of Cystic Fibrosis Carriers

Abstract

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in , the cystic fibrosis transmembrane conductance regulator gene. People with CF experience a wide variety of medical conditions that affect the pulmonary, endocrine, gastrointestinal, pancreatic, biliary, and reproductive systems. Traditionally, CF carriers, with one defective copy of , were not thought to be at risk for CF-associated diseases. However, an emerging body of literature suggests that heterozygotes are at increased risk for many of the same conditions as homozygotes. For example, heterozygotes appear to be at increased risk for chronic pancreatitis, atypical mycobacterial infections, and bronchiectasis. In the United States alone, there are almost 10 million CF carriers. Universal newborn screening and prenatal genetic screening will identify more. Thus, there is a critical need to develop more precise estimates of health risks attributable to the CF carrier state across the lifespan.

Keyword(s): carrier, CFTR, cystic fibrosis
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042120-020148
2022-01-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042120-020148.html?itemId=/content/journals/10.1146/annurev-med-042120-020148&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Stoltz DA, Meyerholz DK, Welsh MJ. 2015. Origins of cystic fibrosis lung disease. N. Engl. J. Med. 372:351–62
     [Google Scholar]
  2. 2. 
    Elborn JS. 2016. Cystic fibrosis. Lancet 388:2519–31
     [Google Scholar]
  3. 3. 
    O'Sullivan BP, Freedman SD 2009. Cystic fibrosis. Lancet 373:1891–904
     [Google Scholar]
  4. 4. 
    Miller AC, Comellas AP, Hornick DB et al. 2019. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. PNAS 117:1621–27
     [Google Scholar]
  5. 5. 
    Burke D, Harrison M, Fleming C et al. 2017. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J. Cyst. Fibrosis 16:291–98
     [Google Scholar]
  6. 6. 
    Quinton PM. 2007. Cystic fibrosis: lessons from the sweat gland. Physiology 22:212–25
     [Google Scholar]
  7. 7. 
    Quinton PM. 1987. Physiology of sweat secretion. Kidney Int. Suppl. 21:S102–S108
     [Google Scholar]
  8. 8. 
    Emrich HM, Stoll E, Friolet B et al. 1968. Sweat composition in relation to rate of sweating in patients with cystic fibrosis of the pancreas. Pediatr. Res. 2:464–78
     [Google Scholar]
  9. 9. 
    Shwachman H, Mahmoodian A. 1967. Pilocarpine iontophoresis sweat testing results of seven years’ experience. Bibl. Paediatr. 86:158–82
     [Google Scholar]
  10. 10. 
    Kintu B, Brightwell A. 2014. Episodic seasonal pseudo-Bartter syndrome in cystic fibrosis. Paediatr. Respir. Rev. 15:Suppl. 119–21
     [Google Scholar]
  11. 11. 
    Vallières E, Elborn JS. 2014. Cystic fibrosis gene mutations: evaluation and assessment of disease severity. Adv. Genom. Genet. 4:161–72
     [Google Scholar]
  12. 12. 
    Castellani C, Assael BM. 2017. Cystic fibrosis: a clinical view. Cell. Mol. Life Sci. 74:129–40
     [Google Scholar]
  13. 13. 
    Cutting GR. 2010. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. N. Y. Acad. Sci. 1214:57–69
     [Google Scholar]
  14. 14. 
    Cutting GR. 2005. Modifier genetics: cystic fibrosis. Annu. Rev. Genom. Hum. Genet. 6:237–60
     [Google Scholar]
  15. 15. 
    Marson FA. 2018. Disease-modifying genetic factors in cystic fibrosis. Curr. Opin. Pulm. Med. 24:296–308
     [Google Scholar]
  16. 16. 
    Goss CH, Newsom SA, Schildcrout JS et al. 2004. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am. J. Respir. Crit. Care Med. 169:816–21
     [Google Scholar]
  17. 17. 
    Szczesniak R, Rice JL, Brokamp C et al. 2020. Influences of environmental exposures on individuals living with cystic fibrosis. Expert Rev. Respir. Med. 14:737–48
     [Google Scholar]
  18. 18. 
    Mazumdar M, Christiani DC, Biswas SK et al. 2015. Elevated sweat chloride levels due to arsenic toxicity. N. Engl. J. Med. 372:582–84
     [Google Scholar]
  19. 19. 
    Cantin AM, Hanrahan JW, Bilodeau G et al. 2006. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am. J. Respir. Crit. Care Med. 173:1139–44
     [Google Scholar]
  20. 20. 
    Raju SV, Jackson PL, Courville CA et al. 2013. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am. J. Respir. Crit. Care Med. 188:1321–30
     [Google Scholar]
  21. 21. 
    Raynal C, Corvol H. 2020. Variant classifications, databases and genotype-phenotype correlations. Arch. Pédiatr. 27:eS13–eS18
     [Google Scholar]
  22. 22. 
    Shah VS, Ernst S, Tang XX et al. 2016. Relationships among CFTR expression, HCO3− secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies. PNAS 113:5382–87
     [Google Scholar]
  23. 23. 
    Castellani C, Quinzii C, Altieri S et al. 2001. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet. Testing 5:249–54
     [Google Scholar]
  24. 24. 
    UCSF Health 2018. FAQ: Carrier testing for cystic fibrosis Fact sheet, Univ. Calif. San Francisco Med. Cent., San Francisco, CA: https://www.ucsfhealth.org/education/carrier_testing_for_cystic_fibrosis/
    [Google Scholar]
  25. 25. 
    Kaiser Permanente 2008. Cystic fibrosis: everything you need to know about being a carrier Brochure, Kaiser Permanente Oakland, CA: https://mydoctor.kaiserpermanente.org/ncal/Images/GEN_Carrier%20brochure%20CF%2005-08_tcm63-10240.pdf
    [Google Scholar]
  26. 26. 
    Cystic Fibrosis Found 2008. Newborn screening education for parents and families Fact sheet, Cystic Fibrosis Found Bethesda, MD: https://www.cff.org/PDF-Archive/My-Baby-is-a-CF-Carrier/
  27. 27. 
    Anderson CM, Freeman M, Allan J, Hubbard L 1962. Observations on (i) sweat sodium levels in relation to chronic respiratory disease in adults and (ii) the incidence of respiratory and other disease in parents and siblings of patients with fibrocystic disease of the pancreas. Med. J. Aust. 49:965–69
     [Google Scholar]
  28. 28. 
    Batten J, Muir D, Simon G, Carter C. 1963. The prevalence of respiratory disease in heterozygotes for the gene for fibrocystic disease of the pancreas. Lancet 281:1348–50
     [Google Scholar]
  29. 29. 
    Hallett WY, Knudson AG Jr., Massey FJ Jr. 1965. Absence of detrimental effect of the carrier state for the cystic fibrosis gene. Am. Rev. Respir. Dis. 92:714–24
     [Google Scholar]
  30. 30. 
    Orzalesi M, Kohner D, Cook C, Shwachman H. 1963. Anamnesis, sweat electrolyte and pulmonary function studies in parents of patients with cystic fibrosis of the pancreas. Acta Pædiatr 52:267–76
     [Google Scholar]
  31. 31. 
    Kerem B-S, Rommens JM, Buchanan JA et al. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–80
     [Google Scholar]
  32. 32. 
    Rommens JM, Iannuzzi MC, Kerem B-S et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–65
     [Google Scholar]
  33. 33. 
    Wright SW, Morton NE. 1968. Genetic studies on cystic fibrosis in Hawaii. Am. J. Hum. Genet. 20:157–69
     [Google Scholar]
  34. 34. 
    Knudson AG, Wayne L, Hallett WY. 1967. On the selective advantage of cystic fibrosis heterozygotes. Am. J. Hum. Genet. 19:388–92
     [Google Scholar]
  35. 35. 
    Danks D, Allan J, Anderson CM 1965. A genetic study of fibrocystic disease of the pancreas. Ann. Hum. Genet. 28:323–56
     [Google Scholar]
  36. 36. 
    Jorde L, Lathrop G. 1988. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers. Am. J. Hum. Genet. 42:808–15
     [Google Scholar]
  37. 37. 
    Romero IG, Ober C. 2008. CFTR mutations and reproductive outcomes in a population isolate. Hum. Genet. 122:583–88
     [Google Scholar]
  38. 38. 
    Nagel RL, Roth EJ. 1989. Malaria and red cell genetic defects. Blood 74:1213–21
     [Google Scholar]
  39. 39. 
    Lell B, May J, Schmidt-Ott RJ et al. 1999. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin. Infect. Dis. 28:794–99
     [Google Scholar]
  40. 40. 
    Shier W. 1979. Increased resistance to influenza as a possible source of heterozygote advantage in cystic fibrosis. Med. Hypotheses 5:661–67
     [Google Scholar]
  41. 41. 
    Hollander DH. 1982. Etiogenesis of the European cystic fibrosis polymorphism: heterozygote advantage against venereal syphilis?. Med. Hypotheses 8:191–97
     [Google Scholar]
  42. 42. 
    Cassano W. 1985. Cystic fibrosis and the plague. Med. Hypotheses 18:51–52
     [Google Scholar]
  43. 43. 
    Super M, van Schalkwyk D. 1979. Heterozygote advantage in cystic fibrosis: mosquito tests. Clin. Genet. 16:65–68
     [Google Scholar]
  44. 44. 
    Meindl RS. 1987. Hypothesis: a selective advantage for cystic fibrosis heterozygotes. Am. J. Phys. Anthropol. 74:39–45
     [Google Scholar]
  45. 45. 
    Bosch L, Bosch B, De Boeck K et al. 2017. Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory. BMC Infect. Dis. 17:340
     [Google Scholar]
  46. 46. 
    Borzan V, Tomašević B, Kurbel S. 2014. Hypothesis: possible respiratory advantages for heterozygote carriers of cystic fibrosis linked mutations during dusty climate of last glaciation. J. Theor. Biol. 363:164–68
     [Google Scholar]
  47. 47. 
    Kurbel S. 2019. Was the Last Ice Age dusty climate instrumental in spreading of the three “Celtic” diseases (hemochromatosis, cystic fibrosis and palmar fibromatosis)?. Med. Hypotheses 122:134–38
     [Google Scholar]
  48. 48. 
    Padua RA, Warren N, Grimshaw D et al. 1997. The cystic fibrosis delta F508 gene mutation and cancer. Hum. Mutat. 10:45–48
     [Google Scholar]
  49. 49. 
    Quinton PM. 1994. Human genetics: What is good about cystic fibrosis?. Curr. Biol. 4:742–43
     [Google Scholar]
  50. 50. 
    van de Vosse E, Ali S, De Visser AW et al. 2005. Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). Hum. Genet. 118:138–40
     [Google Scholar]
  51. 51. 
    Farrell PM, Koscik RE. 1996. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. Pediatrics 97:524–28
     [Google Scholar]
  52. 52. 
    Feigal RJ, Shapiro BL. 1979. Altered intracellular calcium in fibroblasts from patients with cystic fibrosis and heterozygotes. Pediatr. Res. 13:764–68
     [Google Scholar]
  53. 53. 
    Shapiro BL, Lam LF. 1987. Intracellular calcium in cystic fibrosis heterozygotes. Life Sci 40:2361–66
     [Google Scholar]
  54. 54. 
    Papp Z. 1976. Protein level in the meconium of a homozygotic and a heterozygotic infant with cystic fibrosis. J. Pediatr. 88:151
     [Google Scholar]
  55. 55. 
    Chandra R, Madhavankutty K, Way R 1975. Serum alpha-fetoprotein levels in patients with cystic fibrosis and their parents and siblings. BMJ 1:714–16
     [Google Scholar]
  56. 56. 
    Wilson G, Burdash N, Arnaud P et al. 1976. Carcinoembryonic antigen and cystic fibrosis protein in blood from cystic fibrosis homozygotes and heterozygote carriers. Scand. J. Immunol. 5:829–36
     [Google Scholar]
  57. 57. 
    Baylin SB, Rosenstein BJ, Marton LJ, Lockwood DH. 1980. Age-related abnormalities of circulating polyamines and diamine oxidase activity in cystic fibrosis heterozygotes and homozygotes. Pediatr. Res. 14:921–25
     [Google Scholar]
  58. 58. 
    Lundgren DW, Farrell PM, Di Sant'agnese PA. 1975. Polyamine alterations in blood of male homozygotes and heterozygotes for cystic fibrosis. Clin. Chim. Acta 62:357–62
     [Google Scholar]
  59. 59. 
    Moriceau S, Lenoir G, Witko-Sarsat V. 2010. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. J. Innate Immunity 2:260–66
     [Google Scholar]
  60. 60. 
    Foucard T, Gebre-Medhin M, Gustavson KH, Lindh U. 1991. Low concentrations of sodium and magnesium in erythrocytes from cystic fibrosis heterozygotes. Acta Pædiatr 80:57–61
     [Google Scholar]
  61. 61. 
    Behm JK, Hagiwara G, Lewiston NJ et al. 1987. Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes. Pediatr. Res. 22:271–76
     [Google Scholar]
  62. 62. 
    Lucotte G, Perignon J-L, Lenoir G. 1991. Transient neonatal hypertrypsinaemia as test for ΔF508 heterozygosity. Lancet 337:988
     [Google Scholar]
  63. 63. 
    Castellani C, Picci L, Scarpa M et al. 2005. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Am. J. Med. Genet. Part A 135:142–44
     [Google Scholar]
  64. 64. 
    Spock A, Heick H, Cress H, Logan W. 1967. Abnormal serum factor in patients with cystic fibrosis of the pancreas. Pediatr. Res. 1:173–77
     [Google Scholar]
  65. 65. 
    Bowman BH, Lockhart LH, McCombs ML. 1969. Oyster ciliary inhibition by cystic fibrosis factor. Science 164:325–26
     [Google Scholar]
  66. 66. 
    Besley G, Patrick AD, Norman A. 1969. Inhibition of the motility of gill cilia of Dreissensia by plasma of cystic fibrosis patients and their parents. J. Med. Genet. 6:278–80
     [Google Scholar]
  67. 67. 
    Wilson GB, Bahm VJ. 1980. Synthesis and secretion of cystic fibrosis ciliary dyskinesia substances by purified subpopulations of leukocytes. J. Clin. Investig. 66:1010–19
     [Google Scholar]
  68. 68. 
    Wood JA, Fishman AP, Reemtsma K et al. 1959. A comparison of sweat chlorides and intestinal fat absorption in chronic obstructive pulmonary emphysema and fibrocystic disease of the pancreas. N. Engl. J. Med. 260:951–57
     [Google Scholar]
  69. 69. 
    Peterson EM. 1959. Consideration of cystic fibrosis in adults, with a study of sweat electrolyte values. JAMA 171:1–6
     [Google Scholar]
  70. 70. 
    Karlish A, Tarnoky A. 1960. Mucoviscidosis as a factor in chronic lung disease in adults. Lancet 276:514–15
     [Google Scholar]
  71. 71. 
    Koch E. 1959. Die erbliche Erwachsenen-Mucoviscidosis und ihre Beziehungen zur Ulkuskrankheit. Deutsche Med. Wochenschr. 84:1773–84
     [Google Scholar]
  72. 72. 
    Chillón M, Casals T, Mercier B et al. 1995. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332:1475–80
     [Google Scholar]
  73. 73. 
    Cohn JA, Noone PG, Jowell PS. 2002. Idiopathic pancreatitis related to CFTR: complex inheritance and identification of a modifier gene. J. Investig. Med. 50:247s–255s
     [Google Scholar]
  74. 74. 
    Sharer N, Schwarz M, Malone G et al. 1998. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 339:645–52
     [Google Scholar]
  75. 75. 
    Castellani C, Bonizzato A, Rolfini R et al. 1999. Increased prevalence of mutations of the cystic fibrosis gene in idiopathic chronic and recurrent pancreatitis. Am. J. Gastroenterol. 94:1993–95
     [Google Scholar]
  76. 76. 
    Miller PW, Hamosh A, Macek M Jr. et al. 1996. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am. J. Hum. Genet. 59:45–51
     [Google Scholar]
  77. 77. 
    Gild R, Clay C, Morey S. 2010. Aquagenic wrinkling of the palms in cystic fibrosis and the cystic fibrosis carrier state: a case–control study. Br. J. Dermatol. 163:1082–84
     [Google Scholar]
  78. 78. 
    Pignatti PF, Bombieri C, Marigo C et al. 1995. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum. Mol. Genet. 4:635–39
     [Google Scholar]
  79. 79. 
    Nielsen AO, Qayum S, Bouchelouche PN et al. 2016. Risk of asthma in heterozygous carriers for cystic fibrosis: a meta-analysis. J. Cyst. Fibrosis 15:563–67
     [Google Scholar]
  80. 80. 
    Wang X, Moylan B, Leopold DA et al. 2000. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284:1814–19
     [Google Scholar]
  81. 81. 
    Malagutti N, Cogliandolo C, Franciosi D et al. 2019. Can paranasal sinus computed tomography (CT) screen for cystic fibrosis heterozygotes?. Panminerva Med https://doi.org/10.23736/S0031-0808.19.03588-2
    [Crossref] [Google Scholar]
  82. 82. 
    Polgreen PM, Brown GD, Hornick DB et al. 2018. CFTR heterozygotes are at increased risk of respiratory infections: a population-based study. Open Forum Infect. Dis. 5:ofy219
     [Google Scholar]
  83. 83. 
    Çolak Y, Nordestgaard BG, Afzal S. 2020. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur. Respir. J. 56:2000558
     [Google Scholar]
  84. 84. 
    Yamada A, Komaki Y, Komaki F et al. 2018. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol 19:758–67
     [Google Scholar]
  85. 85. 
    Hadjiliadis D, Khoruts A, Zauber AG et al. 2018. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology 154:736–45.e14
     [Google Scholar]
  86. 86. 
    Shi Z, Wei J, Na R et al. 2021. Cystic fibrosis F508del carriers and cancer risk: results from the UK Biobank. Int. J. Cancer 148:1658–64
     [Google Scholar]
  87. 87. 
    Lekakis J, Abraham P, Balbarini A et al. 2011. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur. J. Cardiovasc. Prev. Rehabil. 18:775–89
     [Google Scholar]
  88. 88. 
    Green DJ, Jones H, Thijssen D et al. 2011. Flow-mediated dilation and cardiovascular event prediction: Does nitric oxide matter?. Hypertension 57:363–69
     [Google Scholar]
  89. 89. 
    Poore S, Berry B, Eidson D et al. 2013. Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis. Chest 143:939–45
     [Google Scholar]
  90. 90. 
    Lopes-Pacheco M. 2016. CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front. Pharmacol. 7:275
     [Google Scholar]
  91. 91. 
    Davies JC. 2015. The future of CFTR modulating therapies for cystic fibrosis. Curr. Opin. Pulmonary Med. 21:579–84
     [Google Scholar]
  92. 92. 
    Mall MA, Galietta LJ. 2015. Targeting ion channels in cystic fibrosis. J. Cyst. Fibrosis 14:561–70
     [Google Scholar]
  93. 93. 
    Solomon GM, Marshall SG, Ramsey BW, Rowe SM. 2015. Breakthrough therapies: cystic fibrosis (CF) potentiators and correctors. Pediatr. Pulmonol. 50:Suppl. 40S3–S13
     [Google Scholar]
  94. 94. 
    Barry PJ, Ronan N, Plant BJ. 2015. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning. Semin. Respir. Crit. Care Med. 36:287–98
     [Google Scholar]
  95. 95. 
    Chang EH, Zabner J. 2015. Precision genomic medicine in cystic fibrosis. Clin. Transl. Sci. 8:606–10
     [Google Scholar]
  96. 96. 
    Wassilew N, Hoffmann H, Andrejak C, Lange C. 2016. Pulmonary disease caused by non-tuberculous mycobacteria. Respir. Int. Rev. Thorac. Dis. 91:386–402
     [Google Scholar]
  97. 97. 
    Philley JV, Griffith DE. 2013. Management of nontuberculous mycobacterial (NTM) lung disease. Semin. Respir. Crit. Care Med. 34:135–42
     [Google Scholar]
  98. 98. 
    Griffith DE, Aksamit T, Brown-Elliott BA et al. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367–416
     [Google Scholar]
  99. 99. 
    Kim J, Farahmand M, Dunn C et al. 2018. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. Sci. Rep. 8:16233
     [Google Scholar]
  100. 100. 
    Fisman D. 2020. Cystic fibrosis heterozygosity: carrier state or haploinsufficiency?. PNAS 117:2740–42
     [Google Scholar]
/content/journals/10.1146/annurev-med-042120-020148
Loading
Clinical Phenotypes of Cystic Fibrosis Carriers
Annual Review of Medicine 73, 563 (2022); https://doi.org/10.1146/annurev-med-042120-020148
/content/journals/10.1146/annurev-med-042120-020148
/content/journals/10.1146/annurev-med-042120-020148
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error